Compare HPE & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HPE | WST |
|---|---|---|
| Founded | 1939 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7B | 18.5B |
| IPO Year | 2015 | 2004 |
| Metric | HPE | WST |
|---|---|---|
| Price | $25.84 | $269.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 7 |
| Target Price | $26.82 | ★ $320.86 |
| AVG Volume (30 Days) | ★ 15.2M | 741.5K |
| Earning Date | 06-02-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.31% | 0.33% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | 0.31 | ★ 6.79 |
| Revenue | ★ $34,296,000,000.00 | $2,886,900,000.00 |
| Revenue This Year | $20.43 | $6.76 |
| Revenue Next Year | $5.68 | $6.25 |
| P/E Ratio | $79.32 | ★ $39.19 |
| Revenue Growth | ★ 13.84 | 1.95 |
| 52 Week Low | $14.55 | $199.89 |
| 52 Week High | $26.44 | $322.34 |
| Indicator | HPE | WST |
|---|---|---|
| Relative Strength Index (RSI) | 65.54 | 65.67 |
| Support Level | $20.19 | $262.93 |
| Resistance Level | $26.43 | $278.04 |
| Average True Range (ATR) | 1.00 | 6.88 |
| MACD | 0.05 | 1.74 |
| Stochastic Oscillator | 99.72 | 93.64 |
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment; it also has a high-performance computing business. HPE's stated goal is to be a complete edge-to-cloud company. Its portfolio enables hybrid clouds and hyperconverged infrastructure.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.